Repaglinide併Metformin複方與Repaglinide單方在第二型糖尿病病人血糖控制的療效差異研究

Effect of Repaglinide and Metformin Combination Therapy Compare With Repaglinide Monotherapy in Type 2 Diabetes Mellitus Treatment

蘇鉯喬

第二型糖尿病 ； 藥物治療 ； Repaglinide ； Metformin ； Combination Therapy

長榮大學醫學研究所學位論文

2017年

碩士

陳宏一

繁體中文

背景 : 根據我國衛福部國民健康署的調查:全台灣有227萬5000名糖尿病友。良好的血糖控制可以減少併發症的產生，複方藥預期可發揮加成的療效達到更穩定的血糖值。本研究欲探討Repaglinide合併Metformin之複方藥與單方藥Repaglinide之療效。 方法： 這是個隨機分組研究。研究組別使用的藥物是Repaglinide 1mg 合併 Metformin 500mg；對照組別使用的藥物是Repaglinide 1mg。在12週後以HbA1c、FPG、PPG等指標評估療效。 結果 : 共有36位受試者完成此研究。HbA1c 在Repaglinide 1mg/Metformin 500mg組和Repaglinide 1mg組分別下降了0.7%和0.3%；FPG和PPG在兩組中分別下降了18.2 mg/dL 和 8.6 mg/ml，且Repaglinide 1mg/Metformin 500mg組在FPG和PPG皆有達到顯著下降。 結論 : Repaglinide 1mg/Metformin 500mg組的合併療法比起Repaglinide1mg單方療法在血糖控制上有更佳的表現，且可避免併發症的發生。

Purpose: According to the demographics from Taiwan National Health Insurance Administration, Ministry of Health and Welfare, there are approximately 138 million diagnosed diabetes people in Taiwan. To control hyperglycemia well can decrease renal, ocular, and neural complications. Combination therapy possibly provide more efficiency and cost-effectiveness. Methods: This is a randomized controlled study. The study group received Repaglinide 1mg/ Metformin 500 mg. The control group received Repaglinide 1mg.The efficacy was evaluated after 12 weeks of treatment, including HbA1C, FPG, and PPG. Results: There were 36 subjects completed the study. The HbA1c levels decreased 0.7 % in Repaglinide/Metformin group in 3 months and was comparable with Repaglinide monotherapy group (0.3%). The FPG and PPG decreased 18.2 mg/dL and 8.6 mg/ml, respectively, which were significantly improved after Repaglinide/Metformin treatment. Conclusions: Repaglinide/Metformin combination therapy provided adequate glycemic control when compared with Repaglinide monotherapy, and without further increase in hypoglycaemia complication.

1. 1. American Diabetes Association. (2010). Standards of Medical Care in Diabetes—2010. Diabetes Care, 33(Supp1), S11-61
   連結：
2. 2. International Diabetes Federation. (2013). IDF Diabetes Atlas, sixth edition.
   連結：
3. 4. World Health Organization. (2015). WHO Global report on diabetes.
   連結：
4. 6. Rao, G. H. (2014). Clinical Complications of Type-2 Diabetes Mellitus in South Asian and Chinese Populations: An Overview. Journal of Diabetes & Metabolism, 5(8), 420.
   連結：
5. 7. NICE Guidelines. (2015). Type 2 diabetes in adults: management [NG28]
   連結：
6. 8. Stratton, I. M. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj, 321(7258), 405-412.
   連結：
7. 9. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 352(9131), 837-853.
   連結：
8. 10. Turner, R. (1996). United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus. Annals of Internal Medicine, 124(1_Part_2), 136.
   連結：
9. 12. Nathan, D.M., Genuth, S., Lachin, J., Cleary, P. (1993).The diabetes Control and Complications Trial Research Group: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 329(14), 977-986.
   連結：
10. 14. Duckworth, W. Abraira C, Moritz T. (2009). Glucose Control and Vascular Complications in Type 2 Diabetes. New England Journal of Medicine, 360(19), 2031-2032.
    連結：
11. 15. Rodney, A. H., Peter, D. R. (2015). Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes, New England Journal of Medicine, 373(10), 977-978.
    連結：
12. 16. Nathan, D. M. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Cobitz and Ambery. Diabetes Care, 32(5).
    連結：
13. 17. Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., Stein, P. P. (2007). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes, Obesity and Metabolism, 9(2), 194-205.
    連結：
14. 18. Kendall, D. M., Cuddihy, R. M., & Bergenstal, R. M. (2009). Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use. The American Journal of Medicine, 122(6).
    連結：
15. 19. Monami, M., Lamanna, C., Marchionni, N., & Mannucci, E. (2008). Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis. Diabetes Research and Clinical Practice, 79(2), 196-203.
    連結：
16. 20. Johansen, O. E., & Birkeland, K. I. (2007). Defining the Role of Repaglinide in the Management of Type 2 Diabetes Mellitus. American Journal of Cardiovascular Drugs, 7(5), 319-335.
    連結：
17. 21. Moses, R., Slobodniuk, R., Boyages, S., Colagiuri, S., Kidson, W., Carter, J., Hopkins, H. (1999). Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care, 22(1), 119-124.
    連結：
18. 22. Morgan, C. L., Poole, C. D., Evans, M., Barnett, A. H., Jenkins-Jones, S., & Currie, C. J. (2012). What Next after Metformin? A Retrospective Evaluation of the Outcome of Second-Line, Glucose-Lowering Therapies in People with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 97(12), 4605-4612.
    連結：
19. 23. Blonde, L., Rosenstock, J., Mooradian, A. D., Piper, B., & Henry, D. (2002). Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. Diabetes, Obesity and Metabolism, 4(6), 368-375.
    連結：
20. 24. González-Ortiz, M., Guerrero-Romero, J. F., Violante-Ortiz, R., Wacher-Rodarte, N., Martínez-Abundis, E., Aguilar-Salinas, C., . . . Beltrán-Jaramillo, T. J. (2009). Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. Journal of Diabetes and its Complications, 23(6), 376-379.
    連結：
21. 25. Derosa, G., D'Angelo, A., Ragonesi, P., Ciccarelli, L., Piccinni, M., Pricolo, F., Salvadeo, S., Montagna, L., Gravina, A., Ferrari, I., Galli, S., Paniga, S. and Cicero, A. (2006). Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. Journal of International Medical Research, 34(5), 545-555.
    連結：
22. 26. Raskin, P., Klaff, L., Mcgill, J., South, S. A., Hollander, P., Khutoryansky, N., & Hale, P. M. (2003). Efficacy and Safety of Combination Therapy: Repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care, 26(7), 2063-2068.
    連結：
23. 27. Raskin, P. (2008). Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 10(12): 1167-77.
    連結：
24. 28. Moses, R. (2009). Repaglinide in combination therapy with metformin in Type 2 diabetes. Experimental and Clinical Endocrinology & Diabetes, 107(S 04), S136-S139.
    連結：
25. 29. Raskin, P., Lewin, A., Reinhardt, R., & Lyness, W. (2009). Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. Diabetes, Obesity and Metabolism, 11(10), 947-952.
    連結：
26. 30. Hiroshi Kamiyama, Effect of Switching from Sulphonylurea to Repaglinide Twice or Three Times Daily for 4 Months on Glycemic Control in Japanese Patients with Type 2 Diabetes. Internal Medicine 2016; 55(13): 1697-1703
    連結：
27. 31. Plosker, G. L., & Figgitt, D. P. (2004). Repaglinide. PharmacoEconomics, 22(6), 389-411
    連結：
28. 32. Palmer, A. J., Roze, S., Lammert, M., Valentine, W. J., Minshall, M. E., Nicklasson, L., Spinas, G. A. (2004). Comparing the Long-term Cost-effectiveness of Repaglinide Plus Metformin Versus Nateglinide Plus Metformin in Type 2 Diabetes Patients with Inadequate Glycaemic Control: An Application of the CORE Diabetes Model in Type 2 Diabetes. Current Medical Research and Opinion, 20(Sup1).
    連結：
29. 33. 陳彥廷Chen, YT. (2014). 二線口服降血糖藥對糖尿病大血管病變之醫療成本效益分析Analysis of cost effectiveness on add-on oral hypoglycemic agents and diabetes related macrovascular complications. 成功大學臨床藥學與藥物科技研究所學位論文
    連結：
30. 3. 中華民國國民健康署 (2015). 歷年糖尿病盛行率
31. 5. Lebovitz, H.E. (1999) Type 2 Diabetes: An Overview. Clinical Chemistry, 45 (8) 1339-1345.
32. 11. Pugh, J.A. (1994). DCCT Group: Intensive insulin therapy reduced microvascular and neurologic outcomes in type 1diabetes mellitus. ACP J Club, 120(2), 30.
33. 13. Gerstein, H.C., Miller, M.E., Byington, R.P. (2008). Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine, 358(24), 2545-2559.